These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 28356155

  • 1. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
    Queiro R, Cañete JD, Montilla C, Abad M, Montoro M, Gómez S, Cábez A, MAAPS study group.
    Arthritis Res Ther; 2017 Mar 29; 19(1):72. PubMed ID: 28356155
    [Abstract] [Full Text] [Related]

  • 2. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis.
    Queiro R, Cañete JD, Montilla C, Abad MA, Montoro M, Gómez S, Cábez A, MAAPS Study Group.
    J Rheumatol; 2019 Jul 29; 46(7):710-715. PubMed ID: 30709957
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E, De Socio A, Perrotta FM.
    J Rheumatol; 2017 Aug 29; 44(8):1159-1164. PubMed ID: 28572467
    [Abstract] [Full Text] [Related]

  • 4. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb 29; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

  • 5. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.
    Queiro R, Brandy A, Rosado MC, Lorenzo A, Coto P, Carriles C, Alperi M, Ballina J.
    J Clin Rheumatol; 2018 Oct 29; 24(7):381-384. PubMed ID: 29509560
    [Abstract] [Full Text] [Related]

  • 6. Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease.
    da Cruz Ribeiro E Souza E, da Silva Carneiro SC, Yazbek MA, de Cássia Menin R, Campanholo CB, Carneiro JN, da Silva CHM, Ranza R.
    Adv Rheumatol; 2020 Sep 22; 60(1):49. PubMed ID: 32962756
    [Abstract] [Full Text] [Related]

  • 7. Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.
    Queiro R, Cañete JD, Montoro M, Gómez S, Cábez A, MAAPS study group.
    Arthritis Res Ther; 2020 Apr 15; 22(1):82. PubMed ID: 32295620
    [Abstract] [Full Text] [Related]

  • 8. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B, Diamantopoulos AP, Høiberg HK, Soldal DM, Kavanaugh A, Haugeberg G.
    J Rheumatol; 2017 Apr 15; 44(4):431-436. PubMed ID: 28148701
    [Abstract] [Full Text] [Related]

  • 9. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
    Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Cañete JD, Perrotta FM.
    RMD Open; 2020 Mar 15; 6(1):. PubMed ID: 32179713
    [Abstract] [Full Text] [Related]

  • 10. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
    Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK, EULAR PsAID Taskforce.
    Ann Rheum Dis; 2014 Jun 15; 73(6):1012-9. PubMed ID: 24790067
    [Abstract] [Full Text] [Related]

  • 11. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E, Parsons WJ, Perrotta FM.
    J Rheumatol; 2016 May 15; 43(5):918-23. PubMed ID: 26980581
    [Abstract] [Full Text] [Related]

  • 12. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
    Queiro R, Cañete JD.
    Clin Rheumatol; 2018 Mar 15; 37(3):661-666. PubMed ID: 29380165
    [Abstract] [Full Text] [Related]

  • 13. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.
    Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L.
    Arthritis Care Res (Hoboken); 2020 Dec 15; 72(12):1772-1779. PubMed ID: 31609525
    [Abstract] [Full Text] [Related]

  • 14. Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study.
    Gratacós J, Pablos JL, de Miguel E, Juanola X, Fernández-Carballido C, Ariza R, Terradas-Montana P, Sastré C, Sanabra C, MiDAS Group.
    Reumatol Clin (Engl Ed); 2023 Apr 15; 19(4):204-210. PubMed ID: 37061282
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G, Kilic E, Nas K, Kamanlı A, Tekeoglu İ.
    Rheumatol Int; 2019 Jan 15; 39(1):73-81. PubMed ID: 30426235
    [Abstract] [Full Text] [Related]

  • 17. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
    Napolitano M, Costa L, Caso F, Megna M, Scarpa R, Balato N, Ayala F, Balato A.
    Clin Rheumatol; 2017 Jul 15; 36(7):1589-1593. PubMed ID: 28567556
    [Abstract] [Full Text] [Related]

  • 18. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR.
    Ann Rheum Dis; 2014 Feb 15; 73(2):407-13. PubMed ID: 23355078
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK, Dissanayake K, Bursill D, Gill T.
    Int J Rheum Dis; 2019 Feb 15; 22(2):262-268. PubMed ID: 30450819
    [Abstract] [Full Text] [Related]

  • 20. A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire.
    Johnson K, Ye JY, Chandran V, Gladman DD.
    Semin Arthritis Rheum; 2019 Oct 15; 49(2):241-245. PubMed ID: 31101369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.